The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Orexo Broadens ZUBSOLV® Product Range and Announces Newly Listed Granted US Patent

17-Feb-2015 | Source : Orexo | Visits : 6590
UPPSALA, Sweden - Orexo AB (publ) announced today in a press release that it has initiated the launch of a new higher ZUBSOLV tablet strength (8.6 mg/2.1 mg buprenorphine/naloxone CIII sublingual tablets). Furthermore, a new patent covering ZUBSOLV was issued in the U.S. The patent is listed in the Orange Book by US Food and Drug Administration and expires in 2032.
In December two new dosage strengths of ZUBSOLV were approved by the US Food and Drug Administration (FDA). Orexo is now prepared to begin distribution and commence the launch of the 8.6 mg dosage, after having received final clearance of the REMS material. The updated REMS material is now published at The new 8.6 mg dosage complements the existing dosage range of 5.7 mg/1.4 mg and 1.4 mg/0.36 mg tablets enabling more patients to receive their optimal dose in one tablet. The new ZUBSOLV dosage strength is based on the same advanced, proprietary sublingual tablet formulation used for the already launched ZUBSOLV tablets, providing higher bioavailability, fast dissolve time, small tablet size, and menthol flavor. The new dosage is expected to be available for patients in the first half of March.
In January the United States Patent and Trademark Office issued a new patent protecting ZUBSOLV, US Patent No. 8,940,330. The patent is the fourth patent listed in the Orange Book by the FDA covering ZUBSOLV and expires on September 18, 2032.
“The continued development of the ZUBSOLV product range is a core element of Orexo’s strategy. We invest significant resources in developing the product through clinical research and pharmaceutical development to the benefit of patients suffering from opioid dependence. A solid patent protection platform is essential to enable these investments. With this latest patent, we gain additional confidence and commitment to our continued efforts to improve the treatment of opioid dependence,” said Nikolaj Sørensen, CEO and President of Orexo AB.
Orexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery. 

Related Articles